The Arcxis system, trade-named Biophalanx(TM), is currently configured in a bench-top format, and is designed with the flexibility to be utilized for the rapid diagnosis of pathogens and the identification of early detection biomarkers for cancer. Ms. Meda will use her extensive experience in the diagnostic and biotech industries to accelerate product beta-testing, applications development programs, and guide the company's commercial product introductions. "The technologies being developed at Arcxis will fill a large gap in the diagnostic and clinical market," said Ms. Meda. "The future of diagnostics will need economical, rapid, reliable systems that can be deployed in environments close to the clinician for improved patient support."
Ms. Meda is well known among business leaders in the corporate diagnostic community and venture capital groups specializing in diagnostic investments. Prior to joining Arcxis, Chris provided strategic product commercialization and financing guidance to a number of diagnostic-focused companies. She has held executive positions at Hoffman-LaRoche, Bio-Rad Laboratories, Diagnostic Products Corporation (now Siemens), Meridian Diagnostics and Schering AG Pharmaceuticals. Most recently Ms. Meda was President and COO at Diamics (now part of Inverness Medical Innovations) where she helped to focus their effort on a medical device and diagnostic test for cervical cancer.
Arcxis Biotechnologies is a developer of systems for disease pathogen detection and clinical diagnostics. The company has been funded by Claremont Creek Ventures, Kaiser Permanente Ventures and several SBIR grants. Headquarters are in Pleasanton, California. For additional information, please call (925) 461-1300 or visit www.arcxis.com.
Contact:
Contact: Howard D. Goldstein Chief Commercial Officer Arcxis Biotechnologies Direct 925-461-1300
Source: Arcxis Biotechnologies
